CompletedNCT02205099
A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
This study evaluated the safety of SKL15508 for people with schizophrenia.
Medication studyAges 18–60United States
Understand this study
What did researchers investigate?
This study evaluated the safety of SKL15508 for people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- GlendaleSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateJuly 2014
- Recruitment status
- Completed
- Enrollment listed in the registry
- 39
- Sponsor
- SK Life Science, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1, Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT02205099
- Official title
Show the full official title
A Single-center, Randomized, Double-blind, Flexible-dosage, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia
Recruitment & locations
CompletedGlendale
Questions about this study
What did researchers investigate?
This study evaluated the safety of SKL15508 for people with schizophrenia.
Who is behind this study?
The study sponsor is SK Life Science, Inc.
Did this study involve medication?
Yes. The study involved medication, including SKL15508 and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia